Protective effect of heparin-coated circuits on the platelets during cardiopulmonary bypass
- PMID: 15015647
- DOI: 10.1007/BF02829429
Protective effect of heparin-coated circuits on the platelets during cardiopulmonary bypass
Abstract
To observe the protective effect of heparin-coated circuits (HCC) on the platelet function during cardiopulmonary bypass (CPB), 23 patients with heart valve replacement were studied. The system heparin dose was 3 mg/kg in the control group (n = 15) and heparin-coated circuits in the HCC group (n = 8). Platelet count, alpha-granule membrane protein-140 (GMP-140) concentrations were determined before CPB, at 60 min of CPB, 30 and 60 min after protamine administration, first 12 h after CPB, respectively. At end of CPB the arterial filters in the circuits were observed by electron microscopy. The amount of first 12-h postoperative blood loss was measured. There was significant reduction in platelet loss during and after CPB in the HCC group in contrast to the control group during CPB (P<0.05). During the first 12 h, postoperative blood loss was reduced in the HCC group as compared with that in the control group (218+/-61 ml, vs. 332+/-118 ml, P<0.05). Electron microscopy showed that in the HCC group the filter meshes and their fringes were clear and fragments of floccules were occasionally seen, without adherent cells or only few adherent cells on their surfaces, whereas several cellular and fibrous components were found to adhere to the surfaces of the filter meshes in the control group. This study indicates that heparin-coated circuits might reduce the platelet loss and activation during CPB and improve hemocompatibility of cardiopulmonary bypass equipment.
Similar articles
-
Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.Artif Organs. 1996 Jul;20(7):767-76. doi: 10.1111/j.1525-1594.1996.tb04538.x. Artif Organs. 1996. PMID: 8828766 Clinical Trial.
-
Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.J Thorac Cardiovasc Surg. 1996 Aug;112(2):472-83. doi: 10.1016/S0022-5223(96)70275-1. J Thorac Cardiovasc Surg. 1996. PMID: 8751516 Clinical Trial.
-
Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.Eur J Cardiothorac Surg. 1996;10(6):449-55. doi: 10.1016/s1010-7940(96)80114-x. Eur J Cardiothorac Surg. 1996. PMID: 8817142 Clinical Trial.
-
Improving cardiopulmonary bypass: heparin-coated circuits.J Extra Corpor Technol. 2003 Dec;35(4):312-6. J Extra Corpor Technol. 2003. PMID: 14979422 Review.
-
Heparin-coated cardiopulmonary bypass circuits: current status.Perfusion. 2001 Sep;16(5):417-28. doi: 10.1177/026765910101600512. Perfusion. 2001. PMID: 11565897 Review.
Cited by
-
Evaluation of biocompatible cardiopulmonary bypass circuit use during pediatric open heart surgery.J Extra Corpor Technol. 2006 Mar;38(1):22-6. J Extra Corpor Technol. 2006. PMID: 16637519 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical